Amgen makes progress with its Horizon prize Tepezza, but there's much work left to do

Submitted by admin on February 7, 2024 - 9:22pm

Source:

Fierce Pharma

News Tags:

Amgen

Horizon Therapeutics

M&A

Tepezza

Headline:

Amgen makes progress with its Horizon prize Tepezza, but there's much work left to do

snippet:

After Amgen completed its $27.8 billion buyout of Horizon Therapeutics in October, executives at the California biotech made it a priority to right the course of thyroid eye disease treatment Tepezza—an instant blockbuster which saw a perplexing slide in just its third full year on the market.

Search form

You are here

Amgen makes progress with its Horizon prize Tepezza, but there's much work left to do

Amgen makes progress with its Horizon prize Tepezza, but there's much work left to do